VCEL

Over the past six months, Vericel Corp.'s stock price has been impacted by several events. The company reported strong financial performance with record first-quarter and second-quarter revenues in 2026, leading to raised full-year guidance. In April 2026, Vericel announced a ten-year BARDA contract valued at up to $197 million for the procurement and advanced development of NexoBrid. The company also received FDA approval for MACI commercial manufacturing at its new state-of-the-art facility in Burlington, Massachusetts, in May 2026. An insider sale of 10,000 shares for $402,000 occurred on June 18, 2026. The stock price increased by 33.94% between September 17, 2025, and September 16, 2026, outperforming the S&P500 Index by +0.69% over the past six months. The stock reached a 52-week high of $49.32 on July 30, 2026, and a 52-week low of $28.95 on March 27, 2026.